Clinical Trial Update: Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pharmacokinetics, safety, and efficacy of a granule formulation of selumetinib in children with Neurofibromatosis Type 1-related symp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Selumetinib (granule formulation) (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Neurofibromatosis Type 1 | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-14